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A C2HC zinc finger is essential for 
the RING-E2 interaction of the 
ubiquitin ligase RNF125
Marie-José Bijlmakers1, João M. C. Teixeira2, Roeland Boer3, Maxim Mayzel4, Pilar Puig-Sàrries1, 
Göran Karlsson4, Miquel Coll1,5, Miquel Pons2 & Bernat Crosas1
The activity of RING ubiquitin ligases (E3s) depends on an interaction between the RING domain and 
ubiquitin conjugating enzymes (E2), but posttranslational events or additional structural elements, 
yet largely undefined, are frequently required to enhance or regulate activity. Here, we show for the 
ubiquitin ligase RNF125 that, in addition to the RING domain, a C2HC Zn finger (ZnF) is crucial for 
activity, and a short linker sequence (Li2120-128) enhances activity. The contribution of these regions was 
first shown with truncated proteins, and the essential role of the ZnF was confirmed with mutations at 
the Zn chelating Cys residues. Using NMR, we established that the C2HC ZnF/Li2120-128 region is crucial 
for binding of the RING domain to the E2 UbcH5a. The partial X-ray structure of RNF125 revealed the 
presence of extensive intramolecular interactions between the RING and C2HC ZnF. A mutation at one 
of the contact residues in the C2HC ZnF, a highly conserved M112, resulted in the loss of ubiquitin ligase 
activity. Thus, we identified the structural basis for an essential role of the C2HC ZnF and conclude that 
this domain stabilizes the RING domain, and is therefore required for binding of RNF125 to an E2.
The modification of proteins by ubiquitination is a versatile mechanism that regulates almost every cellular pro-
cess either through the destruction of target proteins or the spatial or temporal alteration of their functions1. 
The specificity of this posttranslational modification is determined by the ubiquitin ligases or E3s that recruit 
the substrates to which ubiquitin becomes covalently attached2. Consistent with this role, the E3s comprise a 
large diverse group of proteins that share the ability to interact with an E2, or ubiquitin conjugating enzyme, via 
a domain that is most frequently a RING, U-box or HECT domain3. Mechanistically, the E3s fall into two cate-
gories, those that covalently bind ubiquitin before transferring it to a substrate, as is the case for the HECT and 
the RING RBR E3s, and those that do not form a covalent ubiquitin-intermediate, as is the case for the U-box 
proteins and the majority of the RING E3s. Of these, the RING domain proteins are the largest group with more 
than 500 highly diverse members encoded in mammalian genomes4.
Major insights into the mechanism by which RING E3s stimulate the transfer of ubiquitin from an E2 to a sub-
strate without covalently binding ubiquitin themselves, have been obtained from structural studies of RING (and 
U-box) domains associated with ubiquitin-loaded E2s5–7. This demonstrated that RING domains exert allosteric 
effects on E2-Ub conjugates, stabilizing a closed conformation whereby ubiquitin is positioned on the E2 in a 
manner that is optimal for nucleophilic attack at the thioester bond by a lysine of the substrate8–10. Nevertheless, 
it is also clear that in many cases the presence of a RING domain is not sufficient and additional events are 
needed, or significantly enhance the function of ubiquitin ligases11. These regulatory mechanisms are still being 
defined, but various principles can be distinguished such as a requirement for homodimerization (e.g. RNF4, 
BIRC7, XIAP, and IDOL)5,12–14, heterodimerization (e.g. in Mdm2-MdmX, BRCA1-BARD1, RING1B-Bmi1)15–18, 
or the binding of small molecules (sphingosine-1-phosphate binding to TRAF219 or PAR binding to RNF146)20. 
Additionally, a role has been described for auxiliary elements of E3s in enhancing ubiquitin release from the E2, 
either through binding to the E2 (e.g. for gp7821,22 and AO7)23 or to the donor ubiquitin on the E2 (e.g in Cbl)24.
1Institut de Biologia Molecular de Barcelona, CSIC, Parc Cientific de Barcelona, 08028 Barcelona, Spain. 2BioNMR 
Laboratory, Inorganic and Organic Chemistry Department, Organic Chemistry Section, University of Barcelona, Parc 
Cientific de Barcelona, 08028 Barcelona, Spain. 3XALOC beamline, ALBA synchrotron (CELLS), 08290 Cerdanyola 
del Valles, Spain. 4Swedish NMR Centre, University of Gothenburg, SE-40530, Gothenburg, Sweden. 5Institute for 
Research in Biomedicine (IRB Barcelona), Parc Cientific de Barcelona, 08028 Barcelona, Spain. Correspondence and 
requests for materials should be addressed to M.-J.B. (email: mariebijlmakers@gmail.com) or B.C. (email: bcnbmc@ 
ibmb.csic.es)
Received: 30 October 2015
accepted: 14 June 2016
Published: 14 July 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:29232 | DOI: 10.1038/srep29232
To obtain new insights into regulatory structures of ubiquitin ligases, we have studied the RING protein 
RNF125 (previously called TRAC-1). RNF125 was first identified as a regulator of T cell activation25, but has also 
been shown to negatively regulate the cytoplasmic viral RNA sensors RIG-I and MDA526, to interfere with HIV 
transcription27 and promote p53 degradation28. Furthermore, variations in RNF125 gene expression levels have 
been linked to progression of HIV infection29, and resistance of melanoma cells to B-raf inhibitors30. Recently, 
mutations in RNF125 have been associated with a new overgrowth syndrome, characterized by macrocephaly as 
well as inflammatory disease31. These diverse roles of RNF125 remain to be further understood.
RNF125 is a small protein (25 kD) that contains, in addition to the RING domain, three zinc fingers (ZnFs) 
and a ubiquitin interacting motif (UIM) (Fig. 1A). So far, only the interactions via the RING and UIM with E2s 
and ubiquitin, respectively, have been demonstrated32. The in vitro ubiquitination activity of RNF125 is readily 
detectable and in cells, this activity correlates with low steady state levels and a short half-life32. RNF125 belongs 
to a protein family with three related members, RNF114, RNF138 and RNF16632 that, despite similarities in 
size, amino acid sequence and domain organization, differ considerably in activity. This is especially the case for 
RNF114, a psoriasis susceptibility gene product33,34, which has very low activity compared to RNF12533. This 
difference in activity between RNF125 and RNF114 was the starting point of our study and led, through the 
generation of chimeras and stop mutants, to the identification of an essential role of the C2HC ZnF in the activ-
ity of RNF125, and a contributing, non-essential role for a linker region. NMR experiments demonstrated that 
the establishment of RING interactions with the E2 depends on the presence of these auxiliary regions. X-ray 
crystallography showed interactions between the RING and C2HC ZnF, whilst mutations at one of these contact 
residues, M112, resulted in an inhibition of ubiquitin ligase activity, elucidating an important structural role of 
the C2HC ZnF. We conclude that the RING and C2HC ZnF form a functional unit that is required for binding 
to the E2.
Results
The RING domain of RNF125 is not sufficient for activity. We previously compared the in vitro ubiq-
uitination activity of RNF125 to that of its relative RNF114 using proteins immunoprecipitated from transfected 
HEK293T cells33. These reactions, performed in the presence of UbcH5a/b/c as E2 proteins, showed significantly 
higher activity for RNF125 than for RNF114. Here, we performed these reactions with GST-fusion proteins purified 
from Escherichia coli and found an even greater difference, with the activity of RNF114 being virtually undetectable 
(Fig. 2A). This indicated that intrinsic features of the proteins are responsible for this difference. To compare RNF125 
and RNF114 proteins further, we made chimeras, exchanging the N-terminal unique domain and RING domain of 
RNF114 with the same part of RNF125, and vice versa (Fig. 1B, see Supplementary Fig. S1 for a sequence compar-
ison of RNF125 and RNF114). The chimera with the RING domain of RNF114, RNF1141-68/RNF125, showed very 
little in vitro ubiquitin ligase activity consistent with the lower activity of RNF114 (Fig. 2A). Surprisingly, the chimera 
with the RING domain of RNF125, RNF1251-75/RNF114, was also inactive despite this RING domain being indis-
pensable for RNF125 activity32,35. Results in HEK293T cells using myc-tagged forms of the chimeras were consistent 
with the in vitro ubiquitination results. Both RNF1141-68/RNF125 and RNF1251-75/RNF114 were expressed at higher 
levels than RNF125 and were affected less by proteasome inhibition, suggestive of lower auto-ubiquitination activity 
in cells (Fig. 2B). Thus, it can be concluded that whereas the RNF125 RING domain is essential, it is not sufficient 
for ubiquitin ligase activity.
The C2HC ZnF is crucial and linker 2 residues contribute to RNF125 activity. To investigate a role for 
the domains located to the C-terminus of the RING domain, the activity of additional RNF125/RNF114 chimeras 
(Fig. 1B) was analyzed. This showed that a chimera with the first 98 amino acids of RNF125, RNF1251-98/RNF114, 
had very little in vitro activity (Fig. 2C), but this was increased by the presence of an additional 22 amino acids in 
RNF1251-120/RNF114, and further by an adjacent 20 residues in RNF1251-140/RNF114. Thus, the region between 
residues 99 and 140 that contains the C2HC ZnF and linker 2 (Li2) (Fig. 1A) seemed to play an important role in 
RNF125 activity.
To exclude the alternative explanation that the RNF114 domains were inhibitory, we made RNF125 stop 
mutants with truncations at residues 99, 123 or 140 (Fig. 1C) and tested these in time course in vitro ubiquiti-
nation assays (Fig. 2D). Consistent with the results of the RNF125/RNF114 chimeras this showed that ubiquitin 
ligase activity was undetectable for RNF125stop99, a construct that contains only the RING domain and adjoining 
linker sequences. Activity was also not detected when the reaction was allowed to proceed to 60 min (Fig. 2D). 
However, the inclusion of the C2HC ZnF domain in RNF125stop123 resulted in increased activity, which was fur-
ther enhanced by the addition of Li2 in RNF125stop140 (Fig. 2D). Two further stop mutants were made to define 
more precisely the region between 123 and 140 that enhances activity. Of these, RNF125stop129 showed increased 
activity compared to RNF125stop123, whereas no further increase was observed with RNF125stop135 (Fig. 2D). Taken 
together, the results with the chimeras and stop mutants demonstrate that the C2HC ZnF of RNF125 is essential 
for ubiquitin ligase activity, and that residues 120–128 of linker 2 (Li2120-128) further enhance activity.
Point mutations at cysteines in the C2HC ZnF inhibit RNF125 activity. To further investigate the 
role of the C2HC ZnF domain, two of the predicted Zn2+ chelating residues, C100 and C103, were mutated to 
alanines (Figs 1D and 3A). This mutant, RNF125C100A/C103A, showed a loss of activity in in vitro ubiquitination 
reactions (Fig. 3B). Importantly, such an inhibition of activity was not observed for proteins with cysteine muta-
tions at either the second or third ZnFs (see Supplementary Fig. S2).
The C2HC ZnF mutant RNF125C100A/C103A also behaved differently from wildtype RNF125 when expressed 
in HEK293T cells. This mutant had higher steady state levels (Fig. 3C,D) and a longer half-life than wildtype 
RNF125 (Fig. 3C), suggesting that it underwent lower auto-ubiquitination. Furthermore, expression levels of 
RNF125C100A/C103A were not greatly affected by proteasome inhibition with MG-132 (Fig. 3D), again in accordance 
www.nature.com/scientificreports/
3Scientific RepoRts | 6:29232 | DOI: 10.1038/srep29232
with the mutant being less extensively auto-ubiquitinated. Therefore, we conclude that disrupting the C2HC ZnF 
structure severely affected ubiquitin ligase activity of RNF125 in vitro and in cells, illustrating the essential role 
of this ZnF domain.
Figure 1. RNF125, RNF114 and the mutants used in this study. (A) Schematic representation of the RNF125 
domain organization. Myr: myristoylation site; UD: unique domain, which is different for the four family 
members RNF114, RNF125, RNF138 and RNF166; Li1, Li2 and Li3 are linker regions; C2HC and C2H2 
are Zn fingers. (B) Diagrams of RNF125, RNF114 and the chimeras of RNF125 and RNF114 used in Fig. 2. 
RNF125 regions are in light grey, RNF114 regions in dark grey. RNF1141-68/RNF125 contains amino acids 
1-68 of RNF114 and the remainder, starting from the equivalent position of RNF114 residue 69, of RNF125; 
Similarly, RNF1251-75/RNF114 contains amino acids 1-75 of RNF125 and the remainder of RNF114, etcetera. 
(C) Diagrams of the RNF125 stop mutants used in Fig. 2. (D) The C2HC ZnF mutant used in Fig. 3. The stars 
indicate the Ala substitutions at Cys100 and Cys103. (E) The RNF125start31/stop129 protein used in the NMR 
experiments in Fig. 5. The protein starts at Pro31 and ends at Pro128. (F) The RNF125 mutants used in Fig. 7. 
The stars indicate mutations introduced at residues L109, M112 and R113 that, based on the crystal structure, 
make contacts with the RING domain.
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The C2HC Zn finger and linker are essential for RING-UbcH5a interactions. To obtain insights 
into how the C2HC ZnF (and Li2120-128) enhance RNF125 activity, we performed NMR titration experiments 
that allow a sensitive detection of protein-protein interactions and an identification of the residues involved. 
For this, 1H-15N heteronuclear single quantum correlation (HSQC) spectra of the E2 UbcH5a were recorded 
before and after the addition of either RNF125stop99 or RNF125stop129. In this way, chemical shift perturbations 
(CSPs) in 15N-UbcH5a caused by either the RING domain alone (RNF125stop99), or the RING domain together 
with the C2HC ZnF plus Li2120-128 (RNF125stop129) could be distinguished. Strikingly, the results showed that 
at the same molar ratio of 1:0.5 (15N-UbcH5a:RNF125 construct) dramatically more and larger CSPs occurred 
with RNF125stop129 than with RNF125stop99 (Fig. 4A). Indeed, some 15N-UbcH5a perturbations were already obvi-
ous at 0.125 molar equivalents of RNF125stop129 (Fig. 4B), whereas those in the presence of 0.5 equivalents of 
RNF125stop99 were still negligible (Fig. 4A). Thus, it can be concluded that the RING domain on its own did not 
bind to UbcH5a, but that this interaction was greatly enhanced by the presence of the C2HC ZnF and Li2120-128.
A backbone assignment of 13C15N-UbcH5a was performed (see Supplementary Fig. S3) to identify the amino 
acids that underwent perturbations in the presence of RNF125stop129. This revealed that extensive CSPs occurred 
at well-defined RING binding sites in the UbcH5a alpha helix 1 and loop L7, as well as at loop L436–39, although 
the latter ones were of a lesser degree (Fig. 4C, shown for a 1:0.9 ratio of 15N-UbcH5a:RNF125stop129). Previously 
described CSPs indicative of allosteric changes induced by RING interactions were also detected, most notably 
at I88 (Fig. 4B,C). This is believed to be important for the release of ubiquitin at the active site Cys8540, where 
CSPs were observed as well (Fig. 4B,C). Additionally, some large CSPs were observed at UbcH5a regions nor-
mally not affected to this extent by the interaction with RING domains. This was most notable for residues at the 
Figure 2. Ubiquitin ligase activity of RNF125/RNF114 chimeras and RNF125 stop mutants. (A) In vitro 
ubiquitination reactions with GST fusion proteins of RNF125, RNF114 and the chimeras, for 60 min at 37 °C, 
were analyzed by Western blotting (WB) with anti-ubiquitin antibody (Ub). Coomassie staining shows the 
input levels of E3s. (B) HEK293T cells transfected with cDNAs for myc-tagged RNF125 or the RNF125/RNF114 
chimeras, were either left untreated (-) or treated with MG-132 (20 μ M) for 2 h. Cell lysates were analyzed by 
Western blotting for RNF125 levels with anti-myc. Blotting for the chaperone protein p23 was used as a loading 
control. (C) In vitro ubiquitination reactions with RNF125 and the indicated chimeras, performed as in panel A. 
Ubiquitination was detected with anti-ubiquitin (Ub) and input levels of the chimeras are shown by anti-GST 
Western blotting. The band around 25 kD in the RNF1251-98/RNF114 lane (Ub WB) most likely represents a 
multimer of ubiquitin. (D) In vitro ubiquitination reactions with GST fusion proteins of RNF125 stop mutants 
were stopped at 0, 10 and 20 min (two panels on left). The reactions were analyzed with anti-ubiquitin antibody 
(Ub) to detect ubiquitination, and subsequently with anti-GST (GST) to detect the fusion proteins. Reactions 
of RNF125stop99 and RNF125stop140 were also run for 60 min. To show relative input levels of E3s, the GST fusion 
proteins were also loaded separately and stained with Coomassie (panel on the right).
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C-terminus of helix 1 (aa 13-16) and to an even greater extent for amino acids 101-104 in helix 2 (Fig. 4B,C). This 
suggests that some non-canonical E2 interactions may be occurring as well.
Most importantly, it can be concluded that the C2HC ZnF and Li2120-128 are essential for establishing interac-
tions between the RING domain and UbcH5a, hence explaining their role in RNF125 activity.
Ubch5a causes extensive chemical shift changes in the C2HC Zn finger and Li2120-128. To study 
the RNF125/UbcH5a interaction further, the reciprocal NMR titration experiments were performed, adding 
unlabeled UbcH5a to 15N-RNF125stop129. During long NMR experiments (> 24 h) spectra changes occurred as 
a result of partial proteolysis of RNF125stop129, which was confirmed by the observation of a lower Mr protein 
(see Supplementary Fig. S4). These slow changes hindered the NMR assignment of RNF125stop129. Therefore, 
we generated a new protein, RNF125start31/stop129, that starts at amino acid 31 (Fig. 1E) and lacks the predicted 
unstructured 30 N-terminal residues, which indeed resulted in a more stable protein. We determined whether 
this protein had similar in vitro ubiquitination activity as RNF125stop129, which was the case (see Supplementary 
Fig. S4). Furthermore, HSQC spectra of RNF125stop129 and RNF125start31/stop129 were almost identical apart from 
the absence of peaks in the central random coil chemical shift area of RNF125start31/stop129, consistent with the lack 
of an unstructured region (see Supplementary Fig. S5). Thus, the absence of the 30 N-terminal amino acids did 
not affect either the activity or overall structure of the protein in a major way.
Backbone assignment of RNF125start31/stop129 could be achieved for 67% of the peaks, which includes half of 
the RING domain and the complete C2HC ZnF and Li2120-128 regions (Fig. 5, see Supplementary Fig. S6 for more 
details). The majority of expected peaks could be detected although some where broad, creating assignment 
gaps. The unassigned peaks cluster in a central region that represents part of the RING domain and linker 1. We 
observed double peak resonances for residues close to the C-terminus and in the C2HC ZnF, probably arising 
from the presence of a C-terminal proline in the truncated construct with the capacity to adopt a cis peptide 
bond41 (see Supplementary Fig. S6).
To investigate the effects of E2 binding, HSQC spectra of 15N-RNF125start31/stop129 were recorded before and 
after the addition of unlabeled UbcH5a at molar equivalents ranging from 0.125 to 2.5. This resulted in large 
CSPs or extensive peak broadening at RING residues that were expected to interact with E2s, such as V39, C40 
and L41 in the first Zn chelating loop and T63 and S64 in the central alpha helix9 (Fig. 5). Peak broadening 
beyond detection was already observed at 0.25 molar equivalents of UbcH5a for some residues in the RING 
domain (see Supplementary Fig. S7 for plots of all titration points). In addition, most residues of the C2HC ZnF 
and Li2120-128 also underwent chemical shift changes or peak broadening (Fig. 5B,C, see Supplementary Fig. S7). 
The most affected regions were the C-terminal residues of the C2HC ZnF and Li2120-128. To ascertain that also in 
these experiments, the absence of the N-terminal region did not influence results, the 15N-RNF125start31/stop129  
CSPs were compared with those obtained in a similar NMR experiment with the longer 15N-RNF125stop129. 
This showed that UbcH5a caused near identical perturbations in 15N-RNF125start31/stop129 and 15N-RNF125stop129 
(Supplementary Fig. S8).
Figure 3. Effects of C2HC ZnF Cys mutations on RNF125 activity. (A) Amino acid sequence of the C2HC 
ZnF for RNF125 and the mutant RNF125C100A/C103A. Black circles: Zn chelating Cys and His; grey boxes: 
mutated residues. (B) In vitro ubiquitination reactions with GST fusion proteins of RNF125 and RNF125C100A/
C103A for 60 min at 37 °C. Ubiquitination was detected with anti-ubiquitin (Ub) and input levels of the chimeras 
with anti-GST Western blotting. (C) HEK293T cells transfected with myc-tagged RNF125 or RNF125C100A/
C103A were incubated with 100 μ g/ml cycloheximide (CHX) for the indicated times. Cell lysates were analyzed by 
Western blotting with anti-myc (RNF125). Detection of actin was used as loading control. (D) HEK293T cells 
transfected with cDNAs for myc-tagged RNF125 or RNF125C100A/C103A were either left untreated (−) or treated 
with MG-132 (20 μ M) for 2 h. Cell lysates were analyzed by Western blotting with anti-myc (RNF125) and with 
anti-actin antibodies as loading controls.
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In summary, from the experiments presented so far, we conclude that both the RING and C2HC ZnF domain 
of RNF125 are needed to form a complex with the E2, and that both domains as well as the Li2120-128 sense the 
formation of the E2-E3 complex.
X-ray structure of RNF125stop129 reveals extensive intramolecular interactions. To obtain addi-
tional structural insights into the relationship between the RING and C2HC ZnF, we attempted the crystallization 
of full length RNF125. Unfortunately, this protein was not soluble enough. However, the structure of the trun-
cated RNF125stop129 was solved at a resolution of 1.55 Å (Table 1). RNF125stop129 shows a compact module in which 
the RING domain and the C2HC ZnF are easily discerned (Fig. 6A, see Supplementary Fig. S9). The predicted 
unstructured N-terminal 30 amino acids were not observed in the electron density. As shown previously, this 
region does not have a major impact on activity and folding of RNF125stop129 (see Supplementary Figs S4 and S5). 
The very low evolutionary sequence conservation of this region also argues against an important structural role 
(see Supplementary Fig. S10).
Figure 4. CSPs in 15N-UbcH5a caused by either RNF125stop99 or RNF125stop129. (A) Overlay of 1H-15N HSQC 
spectra of 0.18 mM 15N-UbcH5a before (black), and after (red) addition of 0.5 molar equivalents of RNF125stop99 
(left) or RNF125stop129 (right). Bar graphs represent the combined 1H and 15N chemical shift perturbations of 
15N-UbcH5a at these molar ratios. The red bars indicate peaks that have broadened beyond detection. Pro 
residues are indicated by (* ). (B) Expanded regions of 1H-15N HSQC spectra for 0.18 mM UbcH5a showing 
specific peaks before (black) and after the addition of RNF125stop129 at 0.125 (blue), 0.25 (grey), 0.5 (pink), 0.9 
(red) molar equivalents. Peaks for residues at known RING binding sites are shown: I6 in helix 1, K63 in loop 4, 
L97 in loop 7; C85 is the active site Cys; I88 undergoes allosteric changes upon RING binding; L103 is present in 
helix 2.(C) Combined 1H and 15N chemical shift perturbations of 0.18 mM 15N-UbcH5a at 0.9 molar equivalents 
of RNF125stop129. Assigned residues are in black in the sequence underneath the graph, Pro are indicated by a (* ).  
Red bars indicate residues that broadened beyond detection in the presence of RNF125stop129. The blue bars 
below the graph indicate areas that have been published to undergo extensive CSPs in similar NMR titrations: 
residues 1–12 in helix 1, 58–63 in loop 4 and 94–99 in loop 7. A schematic representation of secondary structure 
elements (α -helices as cylinders and β -sheets as arrows) of UbcH5a is also shown.
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The structure of the RING domain of RNF125 resembles that of other RING domains in the PDB database. 
Overlays with eight RING domains that have been co-crystallized with UbcH5 E2 proteins5,6,12,14,20,42–44 showed 
that RNF125 contains similar E2 interacting surfaces (Fig. 6B) composed of the two zinc chelating loops and part 
of the central α -helix. The C2HC ZnF adopts a β β α fold, typical for ZnF domains, which is capped on both sides 
by α -helices formed by regions Li1 and Li2120-128 (Fig. 6A). The α -helix of Li2120-128 is almost continuous with 
that of the C2HC ZnF, but is kinked at C119. As expected, C100, C103, H115 and C119 coordinate the Zn atom 
(Fig. 6A).
The overlays of RNF125stop129 with RING/UbcH5 complexes (Fig. 6B) predict that upon interaction with an 
E2, the C2HC ZnF/Li2120-128 region would be situated close to alpha helix 1 of the E2. A UbcH5a~Ub conjugate 
was included in the overlay to mark the position of ubiquitin. This showed that the C2HC ZnF/Li2120-128 region is 
unlikely to contact a ubiquitin that is bound to an E2 in the closed conformation (Fig. 6B).
We mapped the CSPs of Figs 4 and 5 onto a model of a RNF125stop129/UbcH5a complex, made by overlaying 
the RNF125stop129 structure with that of RNF146 in a Ubch5a co-crystal20 (Fig. 6C). This showed that, as expected, 
large CSPs can be observed in both RNF125 and UbcH5a at the predicted RING-E2 interface. Outside the RING 
domain of RNF125stop129, the largest CSPs occur at the C-terminus of Li2120-128. This region faces towards the 
C-terminal part of UbcH5a alpha helix 1 (Fig. 6D), where UbcH5a undergoes non-canonical CSPs (at residues 
13–16). Other non-canonical UbcH5a CSPs at residues 101–104 in helix 2 may have been propagated from here 
(Fig. 6E). This may suggest that Li2120-128 makes direct contacts with the E2, but this remains to be established 
directly.
Interestingly, the structure demonstrates that extensive intramolecular interactions take place between the 
RING domain and the C2HC ZnF (Fig. 7A). Specifically, electrostatic interactions can be observed between C57 
Figure 5. CSPs caused by UbcH5a in 15N-RNF125start31/stop129. (A) Overlay of 1H-15N HSQC spectra of 
0.2 mM 15N-RNF125start31/stop129 collected at 600 MHz before (black), and after addition of 2 molar equivalents 
of UbcH5a (red). Specific peaks shown in panel B are indicated by arrows. (B) Expanded regions of 1H-15N 
HSQC spectra showing specific residues in the RING domain, C2HC ZnF and Li2120-128, respectively. Overlays 
are shown of 0.2 mM 15N-RNF125start31/stop129 before (black), or after UbcH5a was added at a molar ratio of 
0.25 (blue), 0.5 (grey), 1 (pink) or 2 (red). Some peaks (V39, L41, R113) broadened beyond detection at 
the higher molar ratios of UbcH5a. (C) A plot of the combined 1H and 15N chemical shift perturbations for 
15N-RNF125start31/stop129 residues obtained at 2 molar equivalents of UbcH5a (see A). Assigned residues are in 
black in the sequence underneath the graph, Pro residues are indicated by (* ). #indicate T33 and D88 that were 
too broad in our spectra to be included in the CSP calculation. Red bars represent residues that broadened 
beyond detection in the presence of UbcH5a. Diagrams of secondary structure elements (α -helices as cylinders, 
and β -sheets as arrows) and the RNF125stop129 domain organization are also shown.
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coordinating the proximal Zn2+ of the RING domain and R113 in the C2HC ZnF, where R113 makes additional 
hydrophobic contacts with H45 in the RING domain (Fig. 7B). Furthermore, a hydrophobic patch is formed 
between V43 in the RING, and L109/M112 in the C2HC ZnF (Fig. 7C). Additionally, an anchor between the 
RING and Li2120-128 is provided by a strong hydrogen bond (2.6 Å) between E42 Oε2 and the hydroxyl group of 
Tyr122 (Fig. 7D). These extensive interactions provide a structural basis for the essential role of the C2HC ZnF in 
RNF125 activity, and are consistent with the concept that the RING and C2HC ZnF together form a functional 
unit required for binding to the E2.
Mutations at RING contact sites in the C2HC ZnF abolish RNF125 activity. To test the prediction 
that the C2HC ZnF is important for the RING structure, we measured the HSQC spectrum of the RING-only 
construct 15N-RNF125stop99, as well as that of a shorter form that lacks the N-terminal region, 15N-RNF125start31/stop99. 
The spectra of both proteins show low spectral dispersion and non-uniform peak intensities, typical for misfolded 
and aggregated proteins (see Supplementary Fig. S11). Thus, in the absence of the C2HC ZnF and Li2120-128 a 
properly folded RING domain could not be obtained.
To investigate the structural role of the C2HC ZnF further, Ala substitutions were introduced at residues that, 
based on the crystal structure, interact with residues in the RING domain. For this, ZnF residues L109, M112 
and R113 (Fig. 7B,C) were mutated simultaneously in the full length protein (Fig. 7E). Strikingly, the resulting 
mutant, RNF125LMR showed an almost complete lack of in vitro ubiquitin ligase activity (Fig. 7F). These ZnF 
mutations were also introduced into a construct for expression in mammalian cells. In accordance with reduced 
auto-ubiquitination activity, RNF125L109/M112/R113A showed higher steady state levels (Fig. 7G,H), a longer half 
life (Fig. 7G) and less extensive targeting to the proteasome (Fig. 7H) than wild type RNF125. Next, we focused 
on one of these residues, M112, which is highly conserved (see Supplementary Fig. S10) and reported to be 
associated with an overgrowth syndrome characterized by developmental defects and inflammatory disease31. 
Thus, M112 was mutated to an Ala, and to an Ile (Fig. 7E) to generate the RNF125 mutant detected in some of the 
overgrowth syndrome patients31. Strikingly, both single M112 mutations resulted in a drastic reduction in ubiq-
uitin ligase activity of RNF125 (Fig. 7I). Thus, we conclude that the activity of RNF125 is absolutely dependent 
on both the RING and the ZnF domain and that the disruption of this functional unit by a single point mutation 
is sufficient to inhibit activity.
Rnf125stop129
Data collection
 Space group P212121
 Cell dimensions
  a, b, c (Å) 51.67, 52.32, 73.97
  α , β , γ (°) 90, 90, 90
 Resolution (Å)a 50-1.55 (1.59-1.55)
 Rsymb or Rmerge 5.5 (80)
 I/σ I 10.2 (1.3)
 Completeness (%) 94.0 (94.7)
 Redundancy 2.9 (2.9)
Refinement
 Resolution (Å) 50-1.55
 No. reflections 28010 (2192)
 Rworkc/Rfreed 20.9/23.9
 No. atoms
  Protein 1512
  Ligand/ion 11
  Water 132
 B-factors
  Protein 16.8
  Ligand/ion 37.8
  Water 36.0
 R.m.s. deviations
  Bond lengths (Å) 0.021
  Bond angles (°) 2.14
Table 1.  Data collection and refinement statistics. aThroughout the table, the values in parentheses are for 
the outermost resolution shell. bRsym = Σ h,i|Îh − Ih,i|/Σ h Σ i Ih,i , where Îh = (1/nh) Σ i Ih,i and nh is the number of 
times a reflection is measured. cRwork = Σ hkl||Fobs| − k |Fcalc||/Σ hkl |Fobs|. dRfree = Σ hkl⊂T||Fobs| − k|Fcalc||/Σ hkl⊂T |Fobs| 
where T represents a test set comprising ~5% of all reflections excluded during refinement.
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Discussion
The large number and heterogeneity of RING ubiquitin ligases suggests that also many different regulatory mech-
anisms for these proteins exist. Indeed, we have shown that even related proteins, such as RNF125 and RNF114, 
can have extensive differences in activity. Analyzing such differences may lead to important new insights into 
requirements for activity, which was the premise for the current investigation. Using mutational analysis, activity 
based assays, NMR and X-ray crystallography, we have demonstrated the essential role of a C2HC ZnF for the 
interaction of RNF125 with the E2, which originates from the requirement of the C2HC ZnF for the structural 
stability of the RING domain.
At the outset, the generation of RNF125/RNF114 chimeras demonstrated that the RING domain of RNF125 
is not sufficient for activity, which was confirmed with C-terminally truncated stop mutants (Fig. 2). Additional 
constructs showed that the presence of the C2HC ZnF is required, and that mutations at Zn2+ chelating Cys of 
this domain resulted in a loss of activity (Fig. 3). In addition, linker 2 residues 120–128, Li2120-128, were found 
to contribute to activity in a non-essential way (Fig. 2). The loss of activity for a truncated RNF125 protein that 
contains the RING but not the C2HC ZnF/Li2120-128 region, correlated with a loss of interaction with 15N-UbcH5a 
seen by NMR (Fig. 4). The crystal structure of the stop mutant RNF125stop129 showed clear contacts between the 
RING and C2HC ZnF domains (Fig. 6). The same construct showed sharp signals by NMR for most of the RING 
and C2HC ZnF domains (Fig. 6), although the presence of some broad lines suggests that the connecting segment 
may be dynamic.
We hypothesized that the presence of the C2HC ZnF domain could be required for the stability of the RING 
domain. This was confirmed with a construct containing the RING domain sequence but lacking the C2HC 
ZnF/Li2120-128 region, which was found to be unfolded (see Supplementary Fig. S11). Moreover, the essential 
role of the RING-C2HC ZnF interaction was also established by mutations at residues L109, R113 and M112 
in the ZnF that are in direct contact with the RING domain. The triple mutant showed a loss of ubiquitin ligase 
activity in vitro and in cells (Fig. 7). Strikingly, of these three RING interacting residues, only the M112 equivalent 
is not present in RNF114 but is an Ile instead (see Supplementary Fig. S1). Moreover, a M112 to I112 mutation 
was identified in patients with the recently described Tenorio overgrowth syndrome31. This M112 is highly con-
served throughout evolution, also suggesting an important role. A key role for M112 was confirmed with single 
M112A and M112I mutations that showed a severe inhibition of RNF125 in vitro ubiquitin ligase activity (Fig. 7). 
Figure 6. Crystal structure of RNF125stop129; models of UbcH5a interactions. (A) Ribbon diagram of the 
RNF125stop129 structure with the RING domain in green, the C2HC ZnF in blue, the linker region L1 in grey 
and Li2120-128 in pink. A 90° rotated view is also shown. (B) Overlays of the RNF125stop129 structure (orange) 
with eight X-ray structures of RING domains (yellow) co-crystallized with UbcH5 E2 proteins (blue) or with a 
UbcH5a-Ub conjugate (4AP4). Ubiquitin is in purple. Structures from PDB were: 4QPL (RNF146/UbchH5a); 
2YHO (Mylip/UbcH5a); 4V3K (RNF38/UbcH5b); 4AUQ (Birc7/UbcH5b); 4A4C (Cbl/UbcH5b); 3EB6 (IAP/ 
UbcH5b); 3RPG (Bmi/UbcH5c). Some PDB files were altered to depict the RING domain and E2 only. (C) Model 
of RNF125stop129 in association with UbcH5a, generated by overlaying RNF125stop129 with RNF146 in PDB 4QPL. 
The CSPs observed in the NMR experiments of Fig. 4 (15N-UbcH5a/RNF125start31/stop129 at 1:0.9) and Fig. 5 
(15N-RNF125stop129/Ubch5a at 1:2) are highlighted on RNF125stop129 (yellow-orange) and UbcH5a (cyan-blue). 
Residues that broadened beyond detection are in red. A 180° rotated view is also shown.
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Collectively, our experiments show that the RING and C2HC ZnF domains with their linker regions act as a 
functional unit held together by interdomain contacts.
Thus, the primary role of the C2HC ZnF seems to be the stabilization of the RING domain and the Li120-128 
region is likely to support this role. However, the question arises whether the C2HC ZnF/Li120-128 region also par-
ticipates directly in an interaction with the E2. The addition of UbcH5a to 15N-RNF125stop129, caused CSPs in the 
ZnF/Li2120-128 region as well as in the RING domain (Fig. 5, see Supplementary Fig. S7). Since these CSPs include 
Figure 7. Effects of mutations at C2HC ZnF residues that contact the RING domain. (A) RNF125stop129 
structure with side chains showing. Residues involved in intramolecular interactions, also shown in (B–D), 
are highlighted. (B) Residues involved in electrostatic contacts between the C2HC ZnF and RING are in 
orange. R113 (in red) was mutated to Ala in the RNF125LMR mutant (panels E–H). (C) Residues involved in 
hydrophobic contacts between the C2HC ZnF and RING are in green. Residues in red, L109 and M112, were 
mutated (panels E–I). (D) Residues involved in hydrophobic contacts between the Li2120-128 and RING are in 
magenta. (E) Amino acid sequence of the C2HC ZnF for RNF125 and the mutants used in panels (E–I). 
Black circles: Zn chelating Cys and His; grey boxes: mutated residues. (F) In vitro ubiquitination reactions 
with GST fusion proteins of RNF125 and RNF125L109/M112/R113A (LMR) for 60 min at 37 °C. Ubiquitination 
was detected with anti-ubiquitin (Ub) and input levels of the chimeras with Coomassie staining of separately 
loaded equivalent amounts of protein. (G) HEK293T cells transfected with myc-tagged RNF125 or 
RNF125L109A,M112A,R113A (LMR) were incubated with 100 μ g/ml cycloheximide (CHX) for the indicated times. 
Cell lysates were analyzed by Western blotting with anti-myc (RNF125). Detection of tubulin was used as 
loading control. (H) HEK293T cells transfected with cDNAs for myc-tagged RNF125 or RNF125L109A,M112A,R113A 
(LMR) were either left untreated (-) or treated with MG-132 (20 μ M) for 2 h. Cell lysates were analyzed by 
Western blotting with anti-myc (RNF125) and with anti-actin antibodies as loading controls. (I) In vitro 
ubiquitination reactions with GST fusion proteins of RNF125 and the mutants RNF125M112I and RNF125M112A, 
for 60 min at 37 °C. Ubiquitination was detected with anti-ubiquitin (Ub) and input levels of the chimeras with 
anti-GST.
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both exposed and buried residues, some of these may be caused by a rearrangement of the RING-C2HC ZnF 
interaction in an E2 complex. In the reciprocal NMR experiment, CSPs induced in 15N-UbcH5a were predomi-
nantly those expected from canonical RING binding sites, but some large non-canonical CSPs were observed as 
well, most notably at residues 13–16 in UbcH5a helix 1, and 101–104 in helix 2 (Fig. 4). An overlay of structures 
for RNF125stop129 and a RNF146/UbcH5a complex showed that the C2HC ZnF+ Li2120-128 region would be in 
the correct location for an interaction with the C-terminus of UbcH5a helix 1 (aa 13-16), from where allosteric 
changes could be propagated to residues 101–104 (Fig. 6). This is an interesting possibility that warrants future 
exploration by NMR and crystallography with E2-Ub conjugates, especially since K101 and L104 interact with 
ubiquitin in the “closed” conformation, which is important for ubiquitin release5–7. Moreover, an interaction with 
the C-terminal region of UbcH5 helix 1, would be expected to compete with E1 binding to the E210. At present 
we do not exclude secondary contacts between ZnF/Li2120-128 and the E2, but we have no direct evidence for this.
The X-ray structure of RNF125stop129 resembles that of three other partial protein structures with adjacent 
RING and ZnF domains, TRAF645, RAG146 and LNX247. Significantly, the ZnF1 of TRAF6 is also essential for 
E2 interactions, but the mechanism for this is drastically different from that of RNF125. The ZnF1 of TRAF6 has 
no direct effect on the RING domain but fixes the position of an N-terminal region that makes contacts with the 
E245. TRAF6 does not show the extensive contacts between the RING and ZnF as seen in RNF125 (Fig. 8A), and 
its ZnF1 is oriented away from the E2. In the case of RAG1, the ZnF is in a similar position to that of TRAF6 
(Fig. 8B,C), and together with the RING was found to be involved in dimerization46. However, for RNF125 we 
did not detect dimerization in relaxation experiments (see Supplementary Fig. S12). Recently the structure of 
LNX2, a ubiquitin ligase that contains a ZnF on both sides of the RING domain, was solved47. As for RNF125, 
one of the ZnFs was found to be essential for activity as well as for solubility of the RING domain. However, this 
ZnF is located to the N-terminus of the RING and does not adopt a typical ZnF fold. Nevertheless, it is located 
in a similar position to the RNF125 C2HC ZnF (Fig. 8D) and also makes extensive contacts with the first Zinc 
Figure 8. Comparison of the RNF125 structure with that of TRAF6, RAG1 and LNX2. (A) Overlay of the 
RNF125stop129 structure (yellow) with that of TRAF6 RING and ZnF domains (blue) in PDB 3HCU. (B) Overlay 
of the RNF125stop129 structure (yellow) with that of RAG1 RING and ZnF domains (pink) in PDB 1RMD.  
(C) Overlay of RNF125stop129 with TRAF6, RAG1 and LNX2. Colours and PDBs as in (A,B,D). (D) Overlay of 
the RNF125stop129 structure (yellow) with that of LNX2 RING and ZnF domains (green) in PDB 5DIN. Two 
orientations are shown. N-ZnF: N-terminal ZnF; C-ZnF: C-terminal ZnF. (E) LNX2 structure with side chains 
shown for residues that interact at the N-ZnF/RING interface. The N-ZnF and RING are in yellow and purple, 
respectively.
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binding loop of the RING domain (Fig. 8E). The C-terminal ZnF of LNX2, on the other hand, is located in a sim-
ilar position as those of TRAF6 and RAG1 (Fig. 8C). Thus, although distinct in primary and secondary structure, 
the ZnFs of RNF125 and LNX2 seems to perform a comparable structural role.
Despite the differences between these proteins, an important role of the ZnFs flanking the RING domain 
appears as a common element. It can be envisioned that these ZnF domains play a role in regulating ubiquitin 
ligase activities through interactions with ligands (proteins or nucleic acids), metal chelating molecules or post 
translational modifications affecting the contacts, and therefore the stability and activity of the RING domain. We 
are currently exploring these possibilities.
Methods
Reagents. Reagents were from Sigma-Aldrich unless otherwise stated.
Plasmids. All cDNAs were of human origin. For expression of N-terminal GST fusion proteins in Escherichia 
Coli, cDNAs for RNF125, RNF114, UbcH5a were cloned into pGEX4T3 (GE Healthcare). cDNAs for RNF125 
and RNF114 in pcDNA3.1myc/HisA- (Invitrogen), and HA-Ubiquitin in pcDNA3.1 for expression in mamma-
lian cells have been previously described32,33. Point mutations, including those that introduce stop codons, were 
generated using Quickchange lightning (Agilent technologies). cDNAs for RNF125/RNF114 chimeras were made 
by overlapping PCRs and subsequently subcloned into pGEX4T3 and pcDNA3.1myc/HisA-. All constructs were 
verified by DNA sequencing.
Expression and purification of GST fusion proteins. GST-fusion proteins were expressed in Escherichia 
Coli BL21DE3(pLysS) (Novagen), induced with 1 mM isopropyl β -D-1-thiogalactopyranoside (IPTG, Duchefa) 
and purified using glutathione-sepharose beads (GE healthcare) according to the manufacturer’s instructions. 
Bacterial cell pellets were resuspended in 50 mM Tris pH 7.4, 150 mM NaCl, 200 μ M ZnCl2, 1 mM DTT, supple-
mented with protease inhibitors (protease complete inhibitor cocktail EDTA-free, GE Healthcare) and disrupted 
by sonication. The homogenate was centrifuged at 40,000 × g and glutathione-sepharose beads were added to the 
supernatant. For ubiquitination reactions, cultures of 50 ml were grown in LB medium, IPTG induction was for 
2 h at 37 °C and the GST-fusion proteins were left on the glutathione-sepharose beads.
For X-ray crystallography and NMR, proteins were purified from 2 L cultures and induced for 16 h at 20 °C. 
Cultures for NMR were grown in minimal medium (M9) supplemented with 15NH4Cl (Cambridge Isotope 
Laboratories) for HSQC recording, or with both 15NH4Cl and 13C6-D-glucose (Cambridge Isotope Laboratories) 
for backbone assignment. For these applications, the proteins were cleaved from GST with thrombin (Sigma) 
on the beads and thrombin was subsequently removed with benzaminidine-agarose beads (GE healthcare). 
Following another incubation with glutathione-sepharose beads to remove traces of free GST, the proteins were 
concentrated to the desired concentration (Centricon 3 K, Millipore). Protein concentrations were determined 
by Bradford (BioRad) and Nanodrop OD280 reading. Protein purity was monitored by Coomassie gel staining.
Antibodies. Mouse anti-ubiquitin P4D1 and rabbit anti-GST Z-5 were from Santa Cruz. The mouse mono-
clonal (mAb) antibody anti-myc 9E10, and anti-tubulin TUB2.1 were from Sigma, mAb anti-P23 JJ3 from Abcam, 
mAb anti-actin C4 from Millipore and mAb anti-HA HA.11 from Covance. Horse-radish peroxidase-conjugated 
donkey anti-rabbit (GE healthcare) and goat anti-mouse antibodies (Thermoscientific) were used as secondary 
antibodies.
In vitro ubiquitination assays. Standard ubiquitination reactions were performed for 60 min at 37 °C in a 
total volume of 50 μ l, containing 2 μ g E3s (as GST-fusion proteins bound to glutathione-beads), 50 ng E1 (Enzo 
Life Sciences), 1 μ g E2 (Enzo Life Sciences), 2 μ g ubiquitin (BostonBiochem) in 50 mM Tris, pH 7.4; 150 mM 
NaCl; 0.5 mM dithiothreitol (DTT); 10 mM MgATP. For time-course experiments, reactions were started by the 
addition of ATP and stopped by the addition of 5× reducing Laemmli loading buffer (100 mM DTT final con-
centration) and boiling at 95 °C for 5 min. To detect ubiquitination, reactions were separated on either a 10% 
acrylamide gel or a 4–12% NuPAGE (Invitrogen) and transferred to PVDF membrane for Western blotting with 
anti-ubiquitin antibodies.
Cell culture, transfections, inhibitor treatment and analysis. Human embryonic kidney 293T cells 
(HEK293T) were grown in DMEM, supplemented with 10% FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin. 
HEK293T cells were transfected using polyethylenimine (PEI) (Polysciences) with 3 μ g DNA per well of a 6 well 
plate. Twenty four hours after transfections, cell were either lysed directly or after incubation with 100 μ g/ml 
cycloheximide or 20 μ M MG-132 (Santa Cruz Biotech) as indicated. Cells were lysed in NP-40 buffer (1% 
NonidetP-40, 20 mM Tris pH 7.6, 150 mM NaCl), supplemented with protease inhibitors (GE Healthcare), and left 
on ice for 30 min. Nuclei and cell debris were removed by centrifugation at 13,000 × g for 5 min at 4 °C. Cell lysates 
were denatured in reducing Laemmli sample buffer for 5 min. at 95 °C, separated on 10% SDS-polyacrylamide 
gels and transferred to PVDF for Western blotting.
NMR spectroscopy, chemical shift perturbations, backbone assignment. 1H-15N-HSQC spectra 
of 15N-labeled samples were recorded in 50 mM Tris pH 7.4, 150 mM NaCl, 200 μ M ZnCl2, 1 mM DTT, 10% D2O 
at 25 °C with a Bruker 600 MHz Advance III spectrometer equipped with a TCI CryoProbe (Unitat de RMN, 
Universitat de Barcelona). NMR spectra were processed using Bruker TopSpin 3.0 and analyzed using CcpNmr48. 
Combined chemical shift differences were calculated using the following equation:
CSP = α∂ + ⋅ ∂[ ( ) ]H H
1
2
2 2  in which α is 0.14, but 0.2 for Gly49. For backbone assignment of 13C15N- 
RNF125start31/stop129 in 50 mM Tris pH 7.0, 50 mM NaCl, 200 μ M ZnCl2, 1 mM DTT, a set of standard triple resonance 
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experiments for the sequential assignment was recorded using incremental non-uniform sampling50 on Bruker 
800 MHz Avance III HD spectrometer equipped with 5 mm TCI CryoProbe (Swedish NMR Centre) at 25 °C. For 
13C15N-UbcH5a assignment in 50 mM Tris pH 7.0, 150 mM NaCl, 200 μ M ZnCl2, 1 mM DTT, recording was performed 
with a Bruker 900 MHz Avance III HD spectrometer equipped with 5 mm TCI CryoProbe (Swedish NMR Centre) at 
25 °C. Spectra were processed using MDDNMR51 and the analysis was performed in CcpNmr Analysis.
X-ray crystallography. A full sparse vapour diffusion matrix screen was performed at 18 °C on a sam-
ple of RNF125stop129 at 952 μ M in 20 mM TRIS buffer pH 7.4 and 137 mM NaCl, using the Phoenix robot (Art 
Robbinson Instruments). Crystals from the following conditions were tested for diffraction: 0.2 M KNO3, 20% 
PEG 3350; 0.1 M HEPES pH 7.5, 10% PEG 8 K; 0.1 M HEPES pH 7.5, 10% PEG 6 K, 5% MPD; 0.1 M TRIS pH 8.5, 
20% ethanol; 0.2 M CaAc2, 0.1 M Cacodylate pH 6.5, 40% PEG 300; 0.1 M PCB buffer (PACT screen, Molecular 
Dimensions, http://www.moleculardimensions.com/), 25% PEG 1500. In addition, crystals were obtained using 
a batch method by storing the protein sample at 454 μ M in phosphate buffer saline (Sigma Aldrich) at 4 °C. The 
crystals belonged to space group P43212 or P212121. The highest resolution obtained was 1.55 Å (see Table 1) 
for crystals belonging to space group P212121. The data was measured at the XALOC beamline (synchrotron 
ALBA, Spain)38 and processed using the XDS package52 and the structure was solved by molecular replacement 
using the PHASER program53 from the CCP4 software package54. Structure refinement was done using REFMAC 
5.8.007355 and manually adjusted using Coot 0.7.256. The final Rcryst /Rfree was 21.2% and 24.4%, respectively. The 
atomic coordinates and the structure factors were deposited in the PDB (reference code 5DKA).
Molecular images were generated using UCSF Chimera57.
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